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ABSTRACT
Purpose: To report the response of choroidal neovascularization (CNV) to intravitreal ranibizumab treatment in the setting of age-
related macular degeneration (AMD) with extensive pre-existing geographic atrophy (GA) and a revision paper. Methods: This is a
revision paper and a retrospective case series of 10 eyes in nine consecutive patients from a photographic database. The patients were
actively treated with ranibizumab for neovascular AMD with extensive pre-existing GA. Patients were included if they had GA at or
adjacent to the foveal center that was present before the development of CNV. The best corrected visual acuity and optical coherence
tomography (OCT) analysis of the central macular thickness were recorded for each visit. Serial injections of ranibizumab were
administered until there was resolution of any subretinal fluid clinically or on OCT. Data over the entire follow-up period were analyzed
for overall visual and OCT changes. All patients had been followed for at least 2 years since diagnosis. Results: The patients received an
average of 6 ± 3 intravitreal injections over the treatment period. Eight eyes had reduced retinal thickening on OCT. On average, the central
macular thickness was reduced by 94 ± 101 µm. Eight eyes had improvement of one or more lines of vision, whereas one eye had dramatic
vision loss and one had no change. The average treatment outcome for all patients was -0.07 ± 4.25 logMAR units, which corresponded
to a gain of 0.6 ± 4.4 lines of Snellen acuity. The treatment resulted in a good anatomic response with the disappearance of the subretinal
fluid, improved visual acuity, and stabilized final visual results. Conclusion: The results of this case series suggest that the use of an
intravitreal anti-vascular endothelial growth factor (VEGF) agent (ranibizumab) for CNV in AMD with extensive pre-existing GA is
effective. Our results are not as striking as published results from large-scale trials of anti-VEGF therapy for subfoveal CNV, presumably
due to the limitation in the baseline visual acuity caused by the underlying GA. The good anatomic response with the disappearance of the
subretinal fluid, improved visual acuity, and stabilized final visual results were consistent with other ranibizumab studies.
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RESUMO
Investigar os resultados da injeção intravítrea de Ranibizumab em pacientes com neovascularização de coróide da degeneração
macular relacionada a idade, com atrofia geográfica extensa, pré-existente e revisão da literatura. Métodos: Este é um artigo de
revisão e também um estudo retrospectivo de 9 pacientes, 10 olhos com neovascularização de coróide da degeneração macular
relacionada à idade, com atrofia geográfica extensa, pré-existente. Os pacientes incluídos apresentaram atrofia geográfica, envolven-
do a fóvea ou adjacente, antes do desenvolvimento da neovascularização de coróide. A melhor correção visual e o exame de
tomografia de coerência óptica (OCT) com analise da espessura macular foram registrados em cada visita. As injeções de ranibizumab
intravítrea foram feitas até a resolução do líquido sub-retiniano pelo OCT e clinicamente. Todos os pacientes tinham seguimento de
6 meses do diagnostico a 2 anos, com média de 16 meses. Resultados: 10 olhos de 9 pacientes incluídos receberam uma média de 6 ±
3 injeções intravítreas de ranibizumab, sendo que 8 apresentaram redução do espessamento macular pelo OCT. A mácula teve o
espessamento reduzido entre 94 ± 101 microns, 8 olhos tiveram melhora de 1 ou mais linhas de visão, um olho teve acentuada
diminuição da visão.e um outro não teve alteração.  A media do resultado do tratamento em  logMAR era -0,07 ± 4.25 correlacionando
um ganho de visão na tabela de Snellen entre 0,6 ± 4.4linhas de visão. Conclusão: Estes resultados sugerem que o uso do Ranibizumab
intravítreo para neovascularização de coróide da degeneração macular relacionada à idade em extensa atrofia geográfica pré-
existente é efetivo. Existem, entretanto, dificuldades na avaliação da acuidade visual destes pacientes em virtude da extensa Atrofia
Geográfica que apresentavam e sobre esta ainda as complicações da neovascularização de coróide, se comparados a casos em que
a neovascularização de coróide não ocorre em atrofia geográfica pré-existente.
Descritores: Degeneração macular;  Atrofia geográfica; Neovascularização de coróide;  Anticorpos monoclonais/uso terapêutico; Retina
INTRODUCTION
Geographic atrophy (GA) is defined in the AREDS studyas one or more well-defined, usually more or less circular, patches of partial or complete depigmentation of
the retinal pigment epithelium (RPE), typically with exposure of
underlying large choroidal blood vessels(1). GA associated with
age-related macular degeneration (AMD) is estimated to affect
nearly 1% of the US population, with this prevalence expected
to increase by 50% by the year 2020(2). GA is a form of advanced
age-related macular degeneration (AMD) that causes central
visual loss and evolves gradually in the central fovea(1).
 Histopathological sections of GA show thinning or absence
of the RPE, closure of the choriocapillaris, and degeneration of
the overlying photoreceptors(3,4). It has been reported(3,4) that
the site of the initial appearance of GA was previously occupied
by drusen, which was large (125 ì m in diameter) in 96% of cases.
In 83% of eyes, the largest drusen was 250 ì m in diameter. The
drusen was usually confluent, with at least two in contact, but it
is sometimes extensive enough to form plaques of drusenoid
material. In addition, the GA is nearly always preceded by the
appearance of hyperpigmentation overlying drusen, followed
by regression of the drusen and the appearance of
hypopigmentation, sometimes accompanied by refractile deposits.
Furthermore, in some eyes, different precursor lesions might
appear simultaneously. Research(5,6) has shown that the strongest
predictor of the subsequent spread of GA is growth in the
previous 2 years. Increased fundus autofluorescence outside
atrophic patches of GA may also be an important predictor of
subsequent progression(7).
Another finding in advanced AMD is choroidal
neovascularization (CNV)(8). Although hyperpigmentation and
hypopigmentation abnormalities of the RPE and drusen are
precursors of GA and CNV, these are related only because they
are advanced forms of age-related macular degeneration(8,9).
The coexistence of GA and CNV has been proved
histopathologically(3,4,10). Some studies(11,12) have shown that the
vascular endothelial growth factor (VEGF)-specific monoclonal
antibodies, ranibizumab and bevacizumab, improve the visual
acuity in patients with AMD and subfoveal CNV(11,14). In the
Marina(11) and Anchor(12) trials with ranibizumab, 94.6% and
96.4% of the patients avoided a 15-letter VA decrease,
respectively. Moreover, 34% and 43% of patients gained at least
15 letters of VA, respectively. The final mean improved by 7.2
and 11.3 letters in the Marina(11) and Anchor(12) trials, respectively.
However, other treatments have been used, including laser
photocoagulation(15,16), verteporfin photodynamic therapy
(PDT)(17), photothrombosis with indocyanine green(18), and
pegaptanib sodium intravitreal injection(19).
This report is a revision paper and investigated the results
of ranibizumab intravitreal monotherapy  in the treatment of
CNV in the context of AMD with extensive pre-existing GA.
METHODS
 This is a revision paper and a retrospective cases series
study from a photographic database center of 10 eyes in 9
consecutive patients under active treatment with ranibizumab
monotherapy for neovascular AMD in the setting of pre-existent
Geographic Atrophy. Patients were included if they had GA at or
adjacent to the central fovea that was present before the
development of CNV (Figures 1 to 7). The exclusion criterion was
no prior treatment of CNV from AMD with extensive pre-existing
GA only permissible in the AREDS formulation(20). The best
corrected visual logMAR and Snellen schedule, color fundus
photography, fluorescein angiography, and optical coherence
tomography (OCT) were obtained each visit. We used Heidelberg
OCT to analyze the central macular thickness, which we recorded
each month. Ranibizumab monotherapy was injected intravitreal
monthly until there was resolution of the subretinal fluid clinically
or by OCT (criteria of retreatment) for a 2-year period. Data on
the overall visual and OCT changes over the entire follow-up 2-
year period were analyzed. All patients were followed for at least
6 months (mean 16 months) and up to 2 years after diagnosis.
RESULTS
 The study included 10 eyes from 9 patients who had been
treated with ranibizumab as monotherapy. The patients received
an average of 6 ± 3 intravitreal injections over the treatment
period. Eight eyes had reduced retinal thickening on OCT. On
average, the central macular thickness was reduced by 94 ± 101
µm. Eight  eyes had an improvement of one or more lines of
vision, whereas one eye had dramatic vision loss and one eye
hasn’t change in his vision . The average treatment outcome for
all patients was –0.07 ± 4.25 logMAR units, which corresponded
to a gain of 0.6 ± 4.4 lines of Snellen acuity.
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Choroidal neovascularization and GA are advanced forms
of AMD according the AREDS reports(1) and others(8,10). When
CNV develops in eyes with GA, it can cause both an abrupt drop
in visual acuity and progression to central vision loss.8,10 The
AREDS data(2) indicate that about one-third of the participants
had central GA at the time when GA was first identified,  there
was a median time to progression from GA to central GA of 2
years. Visual acuity is often decreased before the development
of central GA; for those who do not develop CNV, vision is
expected to decline an additional 22 letters on average during
the next 5 years. Eyes that develop subsequent CNV have an
even worse prognosis.
The reported 2-year rate of 18% and 4-year rate of 34% of
CNV in eyes with GA is compatible with the MPS study(15) and
that of Sunness et al.(10) Other studies(21,23) reported similar rates
of CNV developing in eyes with GA . This is a high incidence and
disproves the impression that GA protects against the
development of CNV. In a study of the treatment of extrafoveal
CNV from AMD, the MPS(15) included 11 participants with GA
Figure 1: Choroidal hemorrhage from occult CNV in geographic atrophy, patient number 6
Figure 2: Patient number 6: OCT
before treatment showing thinning
along the temporal aspect of the cen-
tral macula, and some diffuse
thickening as well as some cystoid
abnormalities around the nasal aspect
of the central macula
Figure 3: OCT after treatment
showing resolution of  findings
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and without CNV in the fellow eye at baseline. Over a 5-year
period, five (45%) patients went on to develop CNV in the GA
eye. The MPS report included participants from the juxtafoveal
and subfoveal AMD trials.
In a case report on a patient with GA(3), with
clinicopathological evaluation, in whom the existence of CNV
was not initially suspected and a fluorescein angiogram had not
revealed CNV, the researchers noted that CNV developed in
one eye with GA in areas of residual choriocapillaris and pigment
epithelium, while no CNV developed in the fellow eye with GA
despite breaks in Bruch’s membrane, presumably because the
breaks occurred in areas without residual choriocapillaris and
RPE, similar to the study by Sunness et al.(10) Similar to our
study, CNV did not grow over atrophy and was seen to develop
at the edge of the GA (Yannuzzi L, personal communication) or
in spared areas within the GA.
In our study, eight eyes had improvement of one or more
lines of vision, whereas one eye had dramatic vision loss and one
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Figure 4: Extensive geographic atrophy, patient number 7 Figure 5: Choroidal hemorrhage from occult CNV in geographic
atrophy, patient number 7
Figure 6: Extensive geographic atrophy, patient number 9
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had no change.
The patients received an average of 6 ± 3 intravitreal
injections over the treatment period. Most of them (8 out 9
patients) had reduced retinal thickening on OCT. On average,
the central macular thickness was reduced by 93 ± 105 µm. The
average treatment outcome for all patients was –0.07 ± 4.25
logMAR units, which corresponded to a gain of 0.6 ± 4.4 lines of
Snellen acuity.
The Marina(11) and Anchor(12) studies proved the efficacy
of anti-VEGF therapy with ranibizumab in the treatment of
subfoveal CNV. Eight of our 10 patients improved their vision
with ranibizumab treatment for CNV in AMD with extensive
pre-existing GA and   reports of ranibizumab treatment of
choroidal neovascularization in the setting of pre-existing
Geographic Atrophy from AMD(24,25) with  similar results as:
good anatomic response with disappearance of the subretinal
fluid, improved visual acuity  and stabilized final visual results
consistent with others ranibizumab studies(11,12,24,25).
Figure 7: Choroidal hemorrhage from occult CNV in geographic
atrophy, patient number 9
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CONCLUSION
 The results of this cases series suggest that the use of an
intravitreal anti-VEGF agent (ranibizumab) for CNV in AMD
with extensive pre-existing GA is effective for these  patients.
Our results are not as striking as the results of large-scale trials
of anti-VEGF therapy for subfoveal CNV, presumably due to
the limitation of the baseline visual acuity caused by the
underlying GA.
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